Idexx Laboratories Free Cash Flow (FCF) History (IDXX)
Idexx Laboratories reported $1.06B in free cash flow for fiscal 2025, an increase of 30.82% from the previous fiscal year, with a free cash flow margin of 24.56%.
View full Idexx Laboratories company overviewIdexx Laboratories free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.06B | $249.1M | +30.82% | +24.56% |
| 2024 | 2024-12-31 | $808.1M | $35.2M | +4.55% | +20.73% |
| 2023 | 2023-12-31 | $772.9M | $378.7M | +96.09% | +21.11% |
| 2022 | 2022-12-31 | $394.1M | −$241.9M | −38.03% | +11.71% |
| 2021 | 2021-12-31 | $636.0M | $94.9M | +17.54% | +19.78% |
| 2020 | 2020-12-31 | $541.1M | $236.9M | +77.88% | +19.99% |
| 2019 | 2019-12-31 | $304.2M | $19.9M | +6.98% | +12.64% |
| 2018 | 2018-12-31 | $284.3M | −$14.6M | −4.87% | +12.85% |
| 2017 | 2017-12-31 | $298.9M | $24.7M | +9.02% | +15.18% |
| 2016 | 2016-12-31 | $274.2M | $135.3M | +97.40% | +15.44% |
| 2015 | 2015-12-31 | $138.9M | −$36.4M | −20.79% | +8.67% |
| 2014 | 2014-12-31 | $175.3M | $6.9M | +4.12% | +11.80% |
| 2013 | 2013-12-31 | $168.4M | $3.6M | +2.18% | +12.23% |
| 2012 | 2012-12-31 | $164.8M | −$3.4M | −2.05% | +12.74% |
| 2011 | 2011-12-31 | $168.2M | $28.3M | +20.23% | +13.80% |
| 2010 | 2010-12-31 | $139.9M | $15.6M | +12.58% | +12.68% |
| 2009 | 2009-12-31 | $124.3M | $71.0M | +133.03% | +12.05% |
| 2008 | 2008-12-31 | $53.3M | — | — | +5.21% |
Idexx Laboratories quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $322.5M | $170.9M | +112.68% | +26.51% |
| Q1 2026 | 2026-03-31 | $234.3M | $26.3M | +12.66% | +20.53% |
| Q4 2025 | 2025-12-31 | $326.3M | $93.6M | +40.19% | +29.92% |
| Q3 2025 | 2025-09-30 | $371.2M | $179.2M | +93.36% | +33.59% |
| Q2 2025 | 2025-06-30 | $151.6M | −$63.4M | −29.47% | +13.67% |
| Q1 2025 | 2025-03-31 | $207.9M | $39.6M | +23.54% | +20.83% |
| Q4 2024 | 2024-12-31 | $232.8M | $15.5M | +7.12% | +24.39% |
| Q3 2024 | 2024-09-30 | $192.0M | −$46.3M | −19.45% | +19.68% |
| Q2 2024 | 2024-06-30 | $215.0M | $42.2M | +24.39% | +21.42% |
| Q1 2024 | 2024-03-31 | $168.3M | $23.9M | +16.56% | +17.46% |
| Q4 2023 | 2023-12-31 | $217.3M | $93.1M | +74.96% | +24.10% |
| Q3 2023 | 2023-09-30 | $238.3M | $87.0M | +57.51% | +26.03% |
| Q2 2023 | 2023-06-30 | $172.8M | $137.1M | +383.29% | +18.32% |
| Q1 2023 | 2023-03-31 | $144.4M | $61.5M | +74.25% | +16.04% |
| Q4 2022 | 2022-12-31 | $124.2M | −$54.0M | −30.29% | +14.99% |
| Q3 2022 | 2022-09-30 | $151.3M | $9.1M | +6.42% | +17.98% |
| Q2 2022 | 2022-06-30 | $35.8M | −$175.6M | −83.08% | +4.16% |
| Q1 2022 | 2022-03-31 | $82.9M | −$21.4M | −20.52% | +9.91% |
| Q4 2021 | 2021-12-31 | $178.2M | −$26.6M | −12.98% | +22.24% |
| Q3 2021 | 2021-09-30 | $142.2M | −$31.7M | −18.24% | +17.54% |
| Q2 2021 | 2021-06-30 | $211.4M | $27.8M | +15.14% | +25.59% |
| Q1 2021 | 2021-03-31 | $104.3M | $125.4M | — | +13.41% |
| Q4 2020 | 2020-12-31 | $204.7M | $95.2M | +86.98% | +28.40% |
| Q3 2020 | 2020-09-30 | $173.9M | $78.7M | +82.69% | +24.09% |
| Q2 2020 | 2020-06-30 | $183.6M | $80.3M | +77.69% | +28.79% |
| Q1 2020 | 2020-03-31 | −$21.1M | −$17.3M | — | −3.37% |
| Q4 2019 | 2019-12-31 | $109.5M | $7.0M | +6.79% | +18.09% |
| Q3 2019 | 2019-09-30 | $95.2M | $15.8M | +19.83% | +15.73% |
| Q2 2019 | 2019-06-30 | $103.3M | $12.1M | +13.32% | +16.66% |
| Q1 2019 | 2019-03-31 | −$3.8M | −$15.0M | — | −0.66% |
| Q4 2018 | 2018-12-31 | $102.5M | $1.4M | +1.41% | +18.66% |
| Q3 2018 | 2018-09-30 | $79.4M | −$15.4M | −16.27% | +14.56% |
| Q2 2018 | 2018-06-30 | $91.2M | −$4.1M | −4.30% | +15.70% |
| Q1 2018 | 2018-03-31 | $11.2M | $3.5M | +46.48% | +2.08% |
| Q4 2017 | 2017-12-31 | $101.1M | $15.2M | +17.68% | +19.98% |
| Q3 2017 | 2017-09-30 | $94.9M | $6.7M | +7.54% | +19.29% |
| Q2 2017 | 2017-06-30 | $95.3M | $352,000 | +0.37% | +18.72% |
| Q1 2017 | 2017-03-31 | $7.6M | $2.5M | +50.02% | +1.65% |
| Q4 2016 | 2016-12-31 | $85.9M | $22.0M | +34.40% | +19.40% |
| Q3 2016 | 2016-09-30 | $88.2M | $31.9M | +56.70% | +19.68% |
| Q2 2016 | 2016-06-30 | $94.9M | $38.6M | +68.57% | +20.34% |
| Q1 2016 | 2016-03-31 | $5.1M | $42.7M | — | +1.22% |
| Q4 2015 | 2015-12-31 | $63.9M | $54.6M | +588.60% | +16.00% |
| Q3 2015 | 2015-09-30 | $56.3M | −$19.9M | −26.08% | +13.85% |
| Q2 2015 | 2015-06-30 | $56.3M | −$11.3M | −16.76% | +13.62% |
| Q1 2015 | 2015-03-31 | −$37.7M | −$59.9M | — | −9.85% |
| Q4 2014 | 2014-12-31 | $9.3M | −$40.0M | −81.15% | +2.64% |
| Q3 2014 | 2014-09-30 | $76.2M | $13.3M | +21.25% | +19.86% |
| Q2 2014 | 2014-06-30 | $67.7M | $12.3M | +22.16% | +17.34% |
| Q1 2014 | 2014-03-31 | $22.2M | $21.3M | +2307.37% | +6.17% |
| Q4 2013 | 2013-12-31 | $49.3M | −$5.3M | −9.66% | +13.91% |
| Q3 2013 | 2013-09-30 | $62.8M | $7.1M | +12.66% | +18.57% |
| Q2 2013 | 2013-06-30 | $55.4M | $6.6M | +13.57% | +15.71% |
| Q1 2013 | 2013-03-31 | $923,000 | −$4.8M | −83.91% | +0.28% |
| Q4 2012 | 2012-12-31 | $54.5M | $9.9M | +22.15% | +17.07% |
| Q3 2012 | 2012-09-30 | $55.8M | −$5.7M | −9.27% | +17.67% |
| Q2 2012 | 2012-06-30 | $48.8M | $2.3M | +4.88% | +14.53% |
| Q1 2012 | 2012-03-31 | $5.7M | −$9.9M | −63.32% | +1.78% |
| Q4 2011 | 2011-12-31 | $44.6M | $6.1M | +15.70% | +14.53% |
| Q3 2011 | 2011-09-30 | $61.5M | $17.8M | +40.66% | +20.42% |
| Q2 2011 | 2011-06-30 | $46.5M | −$422,000 | −0.90% | +14.63% |
| Q1 2011 | 2011-03-31 | $15.6M | $4.9M | +45.76% | +5.34% |
| Q4 2010 | 2010-12-31 | $38.6M | $9.0M | +30.28% | +13.60% |
| Q3 2010 | 2010-09-30 | $43.7M | — | — | +16.20% |
| Q2 2010 | 2010-06-30 | $46.9M | — | — | +16.67% |
| Q1 2010 | 2010-03-31 | $10.7M | — | — | +4.00% |
| Q3 2009 | 2009-09-30 | $29.6M | — | — | +11.43% |
Idexx Laboratories free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from $541.1M to $1.06B, a compound annual growth rate of 14.33%. Idexx Laboratories's latest reported quarter, Q2 2026, generated $322.5M in free cash flow, an increase of 112.68% year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Idexx Laboratories filings at SEC.gov ↗